» Articles » PMID: 39291737

Plasma MiRNAs Across the Alzheimer's Disease Continuum: Relationship to Central Biomarkers

Abstract

Introduction: MicroRNAs (miRNAs) play important roles in gene expression regulation and Alzheimer's disease (AD) pathogenesis.

Methods: We investigated the association between baseline plasma miRNAs and central AD biomarkers from the Alzheimer's Disease Neuroimaging Initiative (ADNI; N = 803): amyloid, tau, and neurodegeneration (A/T/N). Differentially expressed miRNAs and their targets were identified, followed by pathway enrichment analysis. Machine learning approaches were applied to investigate the role of miRNAs as blood biomarkers.

Results: We identified nine, two, and eight miRNAs significantly associated with A/T/N positivity, respectively. We identified 271 genes targeted by amyloid-related miRNAs with estrogen signaling receptor-mediated signaling among the enriched pathways. Additionally, 220 genes targeted by neurodegeneration-related miRNAs showed enrichment in pathways including the insulin growth factor 1 pathway. The classification performance of demographic information for A/T/N positivity was increased up to 9% with the inclusion of miRNAs.

Discussion: Plasma miRNAs were associated with central A/T/N biomarkers, highlighting their potential as blood biomarkers.

Highlights: We performed association analysis of microRNAs (miRNAs) with amyloid/tau/neurodegeneration (A/T/N) biomarker positivity. We identified dysregulated miRNAs for A/T/N biomarker positivity. We identified Alzheimer's disease biomarker-specific/common pathways related to miRNAs. miRNAs improved the classification for A/T/N positivity by up to 9%. Our study highlights the potential of miRNAs as blood biomarkers.

Citing Articles

Preclinical Alzheimer's disease shows alterations in circulating neuronal-derived extracellular vesicle microRNAs in a multiethnic cohort.

Reho P, Kalia V, Jackson G, Wang F, Eiten E, Brennan K Alzheimers Dement. 2025; 21(3):e70050.

PMID: 40042514 PMC: 11881609. DOI: 10.1002/alz.70050.


Circulating small RNAs shed new light on dementia risk.

Zannas A Alzheimers Dement. 2025; 21(2):e14546.

PMID: 39868762 PMC: 11851151. DOI: 10.1002/alz.14546.


Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers.

Liu S, Park T, Kruger D, Pena-Centeno T, Burkhardt S, Schutz A Alzheimers Dement. 2024; 20(11):7698-7714.

PMID: 39291737 PMC: 11567826. DOI: 10.1002/alz.14230.

References
1.
Mei L, Nave K . Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 2014; 83(1):27-49. PMC: 4189115. DOI: 10.1016/j.neuron.2014.06.007. View

2.
Zhang H, Zhang L, Zhou D, Li H, Xu Y . ErbB4 mediates amyloid β-induced neurotoxicity through JNK/tau pathway activation: Implications for Alzheimer's disease. J Comp Neurol. 2021; 529(15):3497-3512. DOI: 10.1002/cne.25207. View

3.
Wang R, Zhang J . Clinical significance of miR-433 in the diagnosis of Alzheimer's disease and its effect on Aβ-induced neurotoxicity by regulating JAK2. Exp Gerontol. 2020; 141:111080. DOI: 10.1016/j.exger.2020.111080. View

4.
Samudra N, Lane-Donovan C, VandeVrede L, Boxer A . Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J Clin Invest. 2023; 133(12). PMC: 10266783. DOI: 10.1172/JCI168553. View

5.
Zhang H, Liu W, Ge H, Li K . Aberrant expression of miR-148a-3p in Alzheimer's disease and its protective role against amyloid-β induced neurotoxicity. Neurosci Lett. 2021; 756:135953. DOI: 10.1016/j.neulet.2021.135953. View